Clinical Trial Update: a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a CD19 and CD22-targeted Prime CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Prime CAR-T cell (CD19/CD22-targeted) (CD19 and CD22 targeted Prime CAR-T cell)

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: B-ALL | Phase 1, Phase 2 | Status: RECRUITING